ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Re-Entry MTC for Offenders With MICA Disorders - 1

This study is not yet open for participant recruitment.
Verified by National Institute on Drug Abuse (NIDA), October 2005

Sponsored by: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00249756
  Purpose

The purpose of this study is to examine the transition of offenders with both mental illness and chemical abuse (MICA) disorders from prison to the community, where continued treatment is generally considered necessary to sustain gains made by prison treatment, and to achieve successful outcomes. The project will determine the effectiveness of a modified therapeutic community (Re-Entry MTC) approach as compared to the case management and parole supervision currently provided. The study will also assess the relative impact on treatment outcomes of the type of treatment received while in prison and of the progress achieved in re-entry treatment.


Condition Intervention Phase
Mental Disorders
Substance-Related Disorders
Behavioral: Modified Therapeutic Community
Phase II
Phase III

MedlinePlus related topics:   Mental Health   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title:   Re-Entry MTC for Offenders With MICA Disorders

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Treatment Effectiveness

Secondary Outcome Measures:
  • Prison Treatment and Progress in Re-Entry Treatment

Estimated Enrollment:   0
Study Start Date:   August 2005
Estimated Study Completion Date:   October 2009

Detailed Description:

Offenders having both mental illness and chemical abuse (MICA) disorders are a population of interest, in part because their special needs place exceptional demands on criminal justice and treatment systems, as well as on individuals and families. This study examines the crucial point of transition from prison to the community, where continued treatment for offenders is generally considered necessary to sustain gains made by prison treatment efforts, and to achieve successful outcomes. The project has two specific aims; Aim 1 is to test the effectiveness of Re entry MTC treatment relative to a control condition, and Aim 2 is to assess the relative impact on treatment outcomes of the type of treatment received while in prison and of the progress achieved in re-entry treatment.

On their release from prison, male offenders with MICA disorders who elect to participate in this study (N = 332), will be placed in either the experimental condition, (E) Re-entry Modified Therapeutic Community (Re-entry MTC) or the control condition, (C) Parole Supervision and Case Management currently provided, using a randomized block assignment procedure. The research employs a prospective, longitudinal, repeated measures assessment with five data collection points: baseline (Time 1, or T1) corresponding to entry into the Community Corrections facility and at 3 (T2), 6 (T3), 12 (T4), and 18 (T5) months post-baseline. The major study hypothesis is that the E condition (compared to the C condition) will produce significantly greater improvement in the presenting problems of the study participants, as measured by substance use, mental health symptoms, and criminal activities.

This project will advance scientific knowledge through a controlled study of the effectiveness of the MTC model, with demonstrated success in community settings, as a re-entry strategy for offenders with MICA disorders, thereby expanding the range of treatment models available to such clients in the community. In addition, the study will examine the degree to which prior prison treatment moderates the effectiveness of the Re-entry MTC, or the extent to which positive outcomes are independent of the type of treatment received during the prior incarceration. This distinction will inform program planning by establishing the value of MTC treatment in prison plus MTC during re-entry versus MTC re-entry treatment alone. Finally, the study tests a specific hypothesis about the degree to which the effectiveness of Re-entry MTC treatment is mediated by client progress during reentry, which will increase our understanding of the relationship between progress in treatment and post-treatment outcomes for offenders with MICA disorders.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Male offenders with serious mental illness and co-occurring chemical abuse (MICA) disorders, as the term is currently applied in the CDOC Chemical abuse consists of any substance use or dependence disorder[s] diagnosis. Serious mental disorder[s] diagnosis includes DSM IV categories for: Bipolar Mood Disorders; Major Depressive Disorder; Paranoid/Delusional Disorders; Schizophrenic Disorders; Schizoaffective Disorder; and Post Traumatic Stress Disorder.

Exclusion Criteria:

  • The study has no exclusion criteria other than programmatic criteria that exclude offenders who constitute a threat to themselves or to others in the community, as determined by the Community Corrections Board at the time the offender is placed in a Community Corrections facility.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00249756

Contacts
Contact: Stanley Sacks, Ph.D.     (212)845-4430     stansacks@mac.com    

Locations
United States, Colorado
Arrowhead Correctional Facility     Not yet recruiting
      Caqon City, Colorado, United States, 81215 0300
      Contact: Marlies Schoeneberger, Ph.D.     303-371-8155     maria.schoeneberger@doc.state.co.us    
San Carlos Correctional Facility     Not yet recruiting
      Pueblo, Colorado, United States, 81002
      Contact: Marlies Schoeneberger, Ph.D.     303-371-8155     maria.schoeneberger@doc.state.co.us    
Sterling Correctional Facility     Not yet recruiting
      Sterling, Colorado, United States, 80751
      Contact: Marlies Schoeneberger, Ph.D.     303-371-8155     maria.schoeneberger@doc.state.co.us    

Sponsors and Collaborators

Investigators
Principal Investigator:     Stanley Sacks, Ph.D.     National Development and Research Institutes, Inc.    
  More Information


Related Info  This link exits the ClinicalTrials.gov site
 

Publications:

Study ID Numbers:   NIDA-19982-1, R01-19982-1
First Received:   November 3, 2005
Last Updated:   November 3, 2005
ClinicalTrials.gov Identifier:   NCT00249756
Health Authority:   United States: Federal Government

Study placed in the following topic categories:
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin

Additional relevant MeSH terms:
Pathologic Processes
Disease

ClinicalTrials.gov processed this record on September 23, 2008




Links to all studies - primarily for crawlers